骨质疏松症药物的有效性在2型糖尿病患者中
Tatiane Vilaca1,2, Richard Eastell3
1Mellanby Centre for Musculoskeletal Research, Division of Clinical Medicine, University of Sheffield, Sheffield, UK. t.vilaca@sheffield.ac.uk.
Current osteoporosis reports
|December 13, 2023
概括
大多数骨质疏松症药物似乎对2型糖尿病 (T2D) 患者有效. 本综述总结了对T2D患者群体骨质疏松症药物疗效的证据,发现安全性和有效性与没有糖尿病的人相比.
科学领域:
- 内分泌学 在内分泌学.
- 骨的新陈代谢 骨的新陈代谢
- 老年病的医生 老年病的医生
背景情况:
- 2型糖尿病 (T2D) 是一种全球性流行病,特别影响老年人,他们也面临骨质疏松症的高风险.
- 尽管骨密度正常或增加,但T2D与骨折风险更高有关,这引发了关于骨质疏松症药物疗效的问题.
- 没有随机对照试验专门针对T2D患者进行骨质疏松症治疗.
研究的目的:
- 审查目前关于骨质疏松症药物的有效性在2型糖尿病患者的科学证据.
主要方法:
- 观察性研究的审查.
- 从随机对照试验中分析后期数据.
主要成果:
- 大多数抗骨质疏松症药物在患有或没有2型糖尿病的患者中表现出类似的疗效和安全性.
- 证据表明,骨质疏松症治疗在患有和没有T2D的人群中具有可比的有效性.
结论:
- 目前的证据表明,大多数骨质疏松症药物对2型糖尿病患者有效.
- 进一步的研究和长期安全数据是必要的,以优化治疗策略和改善骨健康结果在这个人群.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
207
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
207
Diabetes: Management and Pharmacotherapy
288
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
288
Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Carbohydrate Metabolism
11.2K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.2K
Insulin: Dosing Regimen and Adverse Effects
179
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
179
Dipeptidyl Peptidase 4 Inhibitors
190
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
190


